Adjuvant treatment of malignant melanoma: where are we?

@article{Ascierto2006AdjuvantTO,
  title={Adjuvant treatment of malignant melanoma: where are we?},
  author={Paolo Antonio Ascierto and Stefania Scala and Alessandro Ottaiano and Ester Simeone and Ileana de Michele and Giuseppe Palmieri and Giuseppe Castello},
  journal={Critical reviews in oncology/hematology},
  year={2006},
  volume={57 1},
  pages={45-52}
}
To date, no standard adjuvant therapy have increased overall survival in patients with malignant melanoma (MM). The effect of interferon alpha as a single agent or in combination has been widely explored in clinical trials. Critical reading of the major international randomised trials showed that response to interferon (IFN) in terms of improvement of overall survival (OS) may not be strictly correlated with the used dosage and that duration of therapy may impact disease-free survival (DFS) but… CONTINUE READING